INDRAMEDCO evidence report
Evidence date: 2026-10-01. Research observations only.
What can I do with this stock?
Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.
Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.
Today: intraday
Evidence unavailable
No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
- No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
Next week: five trading sessions
No qualifying opportunity
No candidate with a primary five-session horizon in the coherent source run.
- No candidate with a primary five-session horizon in the coherent source run.
Long term: one to three years
Research only
A financial screen alone does not establish an investment recommendation.
- A current, source-backed thesis and valuation review is required.
Investment evidence
- Statement coverage
- FULL_STATEMENTS
- Financial source retrieved
- 2026-09-11T23:40:12.084463+00:00
Metrics
- latest_annual_period
- 2026-03-31
- revenue
- 14825100000.0
- net_income
- 1836200000.0
- operating_cash_flow
- 1893500000.0
- free_cash_flow
- 1297000000.0
- total_assets
- 9913600000.0
- total_liabilities
- 2509900000.0
- total_equity
- 7403700000.0
- cash
- 2633000000.0
- total_debt
- 368600000.0
- revenue_growth
- 0.09300628151818091
- earnings_growth
- 0.1405677371265297
- net_margin
- 0.12385751192234791
- roe
- 0.24801112957034996
- debt_to_equity
- 0.04978591785188487
- cash_conversion
- 1.0312057510075154
- free_cash_flow_margin
- 0.08748676231526263
- trailing_pe
- Not supplied
- forward_pe
- Not supplied
- peg_ratio
- Not supplied
- price_to_book
- Not supplied
- dividend_yield
- Not supplied
Other positional research
No qualifying opportunity
No candidate at another positional horizon in the coherent source run.
- No candidate at another positional horizon in the coherent source run.
Decision provenance and limitations
- Decision ID
- decision-41ad41dc64c26a7812721db458fb95197c5f8581a382eb16b5467ac330890359
- Policy
- stock-decisions-v1
- Evidence bundle hash
- cdf0fa36de40a5b9f4825dd69f11f3e2bc92b8d193e9ef288086bfd839697502
- market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
- validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
- financial-statements: ae2b32afc7a18325daace2feb408d2442c9b9a9ca386027654d6bb8bc4432d1f
- daily-price: 26ac421270adf93dc70a314b1de3bb0fa86b8459b3596f096a0a81594575a8f4
- Conditional research decisions are not orders or personalized position sizes.
- Scenario payoffs are assumptions, not probabilities or expected returns.
- A stop price does not guarantee a maximum loss through a gap or illiquidity.
Download the decision evidence as JSON
Numerical report available. Evidence briefing is queued or awaiting retry.
Cached observations and evidence limits
- Price source verification: REPAIRED.
- The cached closing price on 2026-10-01 was INR 338.60.
- The trailing 5-session price return was -8.61%.
- The trailing 20-session price return was -2.83%.
- The trailing 60-session price return was -7.59%.
- The trailing 250-session price return was -24.47%.
- Average cached traded value over twenty sessions was INR 82,308,302.
- The closing price was -45.03% below its highest close in the available trailing year.
- Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-11T23:40:12.084463+00:00 from EODHD.
- The cached financial metric latest annual period is 2026-03-31.
- The cached financial metric revenue growth is 0.09300628151818091.
- The cached financial metric net margin is 0.12385751192234791.
- The cached financial metric roe is 0.24801112957034996.
- The cached financial metric debt to equity is 0.04978591785188487.
- The cached financial metric cash conversion is 1.0312057510075154.
- The cached financial metric free cash flow margin is 0.08748676231526263.
- Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.